{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:43:04Z","timestamp":1774345384575,"version":"3.50.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for engineered ACIs (eACI-VTs) to model the complex interplay between cell product and patient physiology. We motivate utilizing VTs in eACIs to provide decision support and reflect on how eACI-VTs can support the widespread use of eACIs.<\/jats:p>","DOI":"10.1038\/s41746-025-01809-6","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T12:28:59Z","timestamp":1754051339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies"],"prefix":"10.1038","volume":"8","author":[{"given":"Ulrike","family":"Weirauch","sequence":"first","affiliation":[]},{"given":"Markus","family":"Kreuz","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Birkenbihl","sequence":"additional","affiliation":[]},{"given":"Miriam","family":"Alb","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Quaranta","sequence":"additional","affiliation":[]},{"given":"Laurence","family":"Calzone","sequence":"additional","affiliation":[]},{"given":"Sophia","family":"Orozco-Ruiz","sequence":"additional","affiliation":[]},{"given":"Stefanie","family":"Binder","sequence":"additional","affiliation":[]},{"given":"Luise","family":"Fischer","sequence":"additional","affiliation":[]},{"given":"Sol\u00e8ne","family":"Clavreul","sequence":"additional","affiliation":[]},{"given":"Morine","family":"Maguri","sequence":"additional","affiliation":[]},{"given":"Maximilian","family":"Ferle","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Rade","sequence":"additional","affiliation":[]},{"given":"Guillaume","family":"Azarias","sequence":"additional","affiliation":[]},{"given":"Jay R.","family":"Hydren","sequence":"additional","affiliation":[]},{"given":"Jakub","family":"Jamarik","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Schwarz","sequence":"additional","affiliation":[]},{"given":"Zsolt","family":"Sebestyen","sequence":"additional","affiliation":[]},{"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[]},{"given":"Georg","family":"Popp","sequence":"additional","affiliation":[]},{"given":"Chlo\u00e9","family":"Antoine","sequence":"additional","affiliation":[]},{"given":"Manon","family":"Knockaert","sequence":"additional","affiliation":[]},{"given":"Clara T.","family":"Schoeder","sequence":"additional","affiliation":[]},{"given":"David","family":"Fandrei","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Sanges","sequence":"additional","affiliation":[]},{"given":"Vaclovas","family":"Radvilas","sequence":"additional","affiliation":[]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[]},{"given":"Markus","family":"R\u00fcckert","sequence":"additional","affiliation":[]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Schmidt","sequence":"additional","affiliation":[]},{"given":"Carol","family":"Ward","sequence":"additional","affiliation":[]},{"given":"Carl","family":"Steinbeisser","sequence":"additional","affiliation":[]},{"given":"Jean-Marc","family":"Van Gyseghem","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Niarakis","sequence":"additional","affiliation":[]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Neumuth","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[]},{"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[]},{"given":"Regina","family":"Demlova","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Kremer","sequence":"additional","affiliation":[]},{"given":"Stefan","family":"Franke","sequence":"additional","affiliation":[]},{"given":"Holger","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[]},{"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[]},{"name":"On behalf of the CERTAINTY Consortium","sequence":"additional","affiliation":[]},{"given":"Maximilian","family":"Ferle","sequence":"additional","affiliation":[]},{"given":"Jean-Marc","family":"Van Gyseghem","sequence":"additional","affiliation":[]},{"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1809_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1809_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678\u2013689 (2022).","journal-title":"Nat. Med."},{"key":"1809_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32866-0","volume":"13","author":"U Blache","year":"2022","unstructured":"Blache, U., Popp, G., D\u00fcnkel, A., Koehl, U. & Fricke, S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat. Commun. 13, 5225 (2022).","journal-title":"Nat. Commun."},{"key":"1809_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1809_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1809_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/jpm11080745","volume":"11","author":"MN Kamel Boulos","year":"2021","unstructured":"Kamel Boulos, M. N. & Zhang, P. Digital twins: from personalised medicine to precision public health. J. Pers. Med. 11, 745 (2021).","journal-title":"J. Pers. Med."},{"key":"1809_CR7","doi-asserted-by":"publisher","unstructured":"Fischer, R.-P., Volpert, A., Antonino, P. & Ahrens, T. D. Digital patient twins for personalized therapeutics and pharmaceutical manufacturing. Front. Digit. Health 5, https:\/\/doi.org\/10.3389\/fdgth.2023.1302338 (2024).","DOI":"10.3389\/fdgth.2023.1302338"},{"key":"1809_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01073-0","volume":"7","author":"E Katsoulakis","year":"2024","unstructured":"Katsoulakis, E. et al. Digital twins for health: a scoping review. npj Digit. Med. 7, 77 (2024).","journal-title":"npj Digit. Med."},{"key":"1809_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/20552076221149651","volume":"9","author":"T Sun","year":"2023","unstructured":"Sun, T., He, X. & Li, Z. Digital twin in healthcare: recent updates and challenges. Digit. health 9, 20552076221149651 (2023).","journal-title":"Digit. health"},{"key":"1809_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1109\/JBHI.2023.3323688","volume":"28","author":"M Viceconti","year":"2023","unstructured":"Viceconti, M., Vos, M., de, Mellone, S. & Geris, L. Position paper From the digital twins in healthcare to the Virtual Human Twin: a moon-shot project for digital health research. IEEE J. Biomed. Health Inform. 28, 491\u2013501 (2023).","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"1809_CR11","doi-asserted-by":"publisher","unstructured":"Wright, L. & Davidson, S. How to tell the difference between a model and a digital twin. Adv. Model. and Simul. Eng. Sci. 7, https:\/\/doi.org\/10.1186\/s40323-020-00147-4 (2020).","DOI":"10.1186\/s40323-020-00147-4"},{"key":"1809_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"1809_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13696998.2023.2173466","volume":"26","author":"K Karampampa","year":"2023","unstructured":"Karampampa, K., Zhang, W., Venkatachalam, M., Cotte, F.-E. & Dhanda, D. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed\/refractory multiple myeloma patients in Canada and France. J. Med. Econ. 26, 243\u2013253 (2023).","journal-title":"J. Med. Econ."},{"key":"1809_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003486","volume":"10","author":"E Donnadieu","year":"2022","unstructured":"Donnadieu, E. et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J. Immunother. Cancer 10, e003486 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1809_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003487","volume":"10","author":"S Guedan","year":"2022","unstructured":"Guedan, S. et al. Time 2EVOLVE: predicting efficacy of engineered T-cells\u2014How far is the bench from the bedside?. J. Immunother. Cancer 10, e003487 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1809_CR16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N. et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J. Clin. Oncol.42, 1665\u20131675 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1809_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J. Immunother. Cancer 10, e004475 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1809_CR18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138, 2499\u20132513 (2021).","journal-title":"Blood"},{"key":"1809_CR19","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J. Hematol. Oncol. 16, 7506\u20137508 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1809_CR20","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.3390\/cancers15225443","volume":"15","author":"Boer","year":"2023","unstructured":"Boer et al. Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities. Cancers 15, 5443 (2023).","journal-title":"Cancers"},{"key":"1809_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.913287","volume":"9","author":"S Hort","year":"2022","unstructured":"Hort, S. et al. Toward rapid, widely available autologous CAR-T cell therapy\u2014artificial intelligence and automation enabling the smart manufacturing hospital. Front. Med. 9, 913287 (2022).","journal-title":"Front. Med."},{"key":"1809_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s44287-024-00025-w","volume":"1","author":"C Tang","year":"2024","unstructured":"Tang, C. et al. A roadmap for the development of human body digital twins. Nat. Rev. Electr. Eng. 1, 199\u2013207 (2024).","journal-title":"Nat. Rev. Electr. Eng."},{"key":"1809_CR23","unstructured":"National Academies of Sciences, Engineering, and Medicine. Foundational Research Gaps and Future Directions for Digital Twins (National Academies Press, 2023)."},{"key":"1809_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang, J., Chen, Y., Jing, Y., Green, M. R. & Han, L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat. Rev. Clin. Oncol. 20, 211\u2013228 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1809_CR25","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade, M. et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat. Cancer 5, 1318\u20131333 (2024).","journal-title":"Nat. Cancer"},{"key":"1809_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ccell.2021.01.004","volume":"39","author":"A Irmisch","year":"2021","unstructured":"Irmisch, A. et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell 39, 288\u2013293 (2021).","journal-title":"Cancer Cell"},{"key":"1809_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","volume":"4","author":"K Kropivsek","year":"2023","unstructured":"Kropivsek, K. et al. Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nat. Cancer 4, 734\u2013753 (2023).","journal-title":"Nat. Cancer"},{"key":"1809_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664688","volume":"11","author":"L Vercellino","year":"2021","unstructured":"Vercellino, L. et al. Current and future role of medical imaging in guiding the management of patients with relapsed and refractory non-hodgkin lymphoma treated with CAR T-cell therapy. Front. Oncol. 11, 664688 (2021).","journal-title":"Front. Oncol."},{"key":"1809_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni, E., Tacchetti, P. & Cavo, M. Imaging in multiple myeloma: How? When?. Blood 133, 644\u2013651 (2019).","journal-title":"Blood"},{"key":"1809_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54306-x","volume":"15","author":"I Amit","year":"2024","unstructured":"Amit, I. et al. The commitment of the human cell atlas to humanity. Nat. Commun. 15, 10019 (2024).","journal-title":"Nat. Commun."},{"key":"1809_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2021.100029","volume":"1","author":"HL Rehm","year":"2021","unstructured":"Rehm, H. L. et al. GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genom. 1, 100029 (2021).","journal-title":"Cell Genom."},{"key":"1809_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/cncr.34080","volume":"128","author":"K O\u2019Rourke","year":"2022","unstructured":"O\u2019Rourke, K. ASCO releases guideline on CAR T-cell therapy: a multidisciplinary team\u2019s recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities. Cancer 128, 429\u2013430 (2022).","journal-title":"Cancer"},{"key":"1809_CR33","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I. & Einsele, H. (eds) The EBMT\/EHA CAR-T Cell Handbook (2022).","DOI":"10.1007\/978-3-030-94353-0"},{"key":"1809_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00397-7","volume":"10","author":"C Ma","year":"2024","unstructured":"Ma, C. & Gurkan-Cavusoglu, E. A comprehensive review of computational cell cycle models in guiding cancer treatment strategies. npj Syst. Biol. Appl. 10, 71 (2024).","journal-title":"npj Syst. Biol. Appl."},{"key":"1809_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-023-00297-2","volume":"9","author":"GV Ildefonso","year":"2023","unstructured":"Ildefonso, G. V. & Finley, S. D. A data-driven Boolean model explains memory subsets and evolution in CD8+ T cell exhaustion. npj Syst. Biol. Appl. 9, 36 (2023).","journal-title":"npj Syst. Biol. Appl."},{"key":"1809_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2019.110125","volume":"489","author":"CG Cess","year":"2020","unstructured":"Cess, C. G. & Finley, S. D. Data-driven analysis of a mechanistic model of CAR T cell signaling predicts effects of cell-to-cell heterogeneity. J. Theor. Biol. 489, 110125 (2020).","journal-title":"J. Theor. Biol."},{"key":"1809_CR37","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.3390\/cancers12123600","volume":"12","author":"M Kondratova","year":"2020","unstructured":"Kondratova, M., Barillot, E., Zinovyev, A. & Calzone, L. Modelling of immune checkpoint network explains synergistic effects of combined immune checkpoint inhibitor therapy and the impact of cytokines in patient response. Cancers 12, 3600 (2020).","journal-title":"Cancers"},{"key":"1809_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41576-023-00618-5","volume":"24","author":"P Badia-I-Mompel","year":"2023","unstructured":"Badia-I-Mompel, P. et al. Gene regulatory network inference in the era of single-cell multi-omics. Nat. Rev. Genet. 24, 739\u2013754 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"1809_CR39","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s42256-022-00534-z","volume":"4","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. scBERT as a large-scale pretrained deep language model for cell type annotation of single-cell RNA-seq data. Nat. Mach. Intell. 4, 852\u2013866 (2022).","journal-title":"Nat. Mach. Intell."},{"key":"1809_CR40","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41592-024-02201-0","volume":"21","author":"H Cui","year":"2024","unstructured":"Cui, H. et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat. Methods 21, 1470\u20131480 (2024).","journal-title":"Nat. Methods"},{"key":"1809_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao, Z. et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 14, 213 (2024).","journal-title":"Blood Cancer J."},{"key":"1809_CR42","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"1809_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet, C., Larghero, J. & Mebarki, M. Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 8, 337\u2013342 (2024).","journal-title":"Blood Adv."},{"key":"1809_CR44","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41586-024-08338-4","volume":"637","author":"JE Rood","year":"2025","unstructured":"Rood, J. E. et al. The Human Cell Atlas from a cell census to a unified foundation model. Nature 637, 1065\u20131071 (2025).","journal-title":"Nature"},{"key":"1809_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.procir.2024.08.022","volume":"125","author":"A Shoshi","year":"2024","unstructured":"Shoshi, A. et al. A flexible digital twin framework for ATMP production\u2014towards an efficient CAR T cell manufacturing. Procedia CIRP 125, 124\u2013129 (2024).","journal-title":"Procedia CIRP"},{"key":"1809_CR46","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.3390\/cancers13122941","volume":"13","author":"LRC Barros","year":"2021","unstructured":"Barros, L. R. C. et al. CARTmath\u2014a mathematical model of CAR-T immunotherapy in preclinical studies of hematological cancers. Cancers 13, 2941 (2021).","journal-title":"Cancers"},{"key":"1809_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005360","volume":"10","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J. Immunother. Cancer 10, e005360 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1809_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.849363","volume":"9","author":"AN Prybutok","year":"2022","unstructured":"Prybutok, A. N., Yu, J. S., Leonard, J. N. & Bagheri, N. Mapping CAR T-cell design space using agent-based models. Front. Mol. Biosci. 9, 849363 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"1809_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad374","volume":"39","author":"M Ruscone","year":"2023","unstructured":"Ruscone, M. et al. Multiscale model of the different modes of cancer cell invasion. Bioinformatics 39, btad374 (2023).","journal-title":"Bioinformatics"},{"key":"1809_CR50","doi-asserted-by":"publisher","unstructured":"B\u00e9al, J., Montagud, A., Traynard, P., Barillot, E. & Calzone, L. Personalization of logical models with multi-omics data allows clinical stratification of patients. Front. Physiol. 9, https:\/\/doi.org\/10.3389\/fphys.2018.01965 (2019).","DOI":"10.3389\/fphys.2018.01965"},{"key":"1809_CR51","doi-asserted-by":"publisher","unstructured":"Thompson, B. & Petri\u0107 Howe, N. Alphafold 3.0: the AI protein predictor gets an upgrade. Nature https:\/\/doi.org\/10.1038\/d41586-024-01385-x (2024).","DOI":"10.1038\/d41586-024-01385-x"},{"key":"1809_CR52","doi-asserted-by":"publisher","unstructured":"Moth, C. W. et al. VUStruct: a compute pipeline for high throughput and personalized structural biology. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.08.06.606224 (2024).","DOI":"10.1101\/2024.08.06.606224"},{"key":"1809_CR53","doi-asserted-by":"publisher","unstructured":"Hitawala, F. N. & Gray, J. J. What does AlphaFold3 learn about antigen and nanobody docking, and what remains unsolved? Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.09.21.614257 (2025).","DOI":"10.1101\/2024.09.21.614257"},{"key":"1809_CR54","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/acs.jcim.4c01877","volume":"65","author":"F Eshak","year":"2025","unstructured":"Eshak, F. & Goupil-Lamy, A. Advancements in nanobody epitope prediction: a comparative study of AlphaFold2Multimer vs AlphaFold3. J. Chem. Inf. Model. 65, 1782\u20131797 (2025).","journal-title":"J. Chem. Inf. Model."},{"key":"1809_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30755-0","volume":"13","author":"D Dimitrov","year":"2022","unstructured":"Dimitrov, D. et al. Comparison of methods and resources for cell-cell communication inference from single-cell RNA-Seq data. Nat. Commun. 13, 3224 (2022).","journal-title":"Nat. Commun."},{"key":"1809_CR56","doi-asserted-by":"publisher","first-page":"923085","DOI":"10.3389\/fsysb.2022.923085","volume":"2","author":"DS Santurio","year":"2022","unstructured":"Santurio, D. S. & Barros, L. R. C. A mathematical model for on-target off-tumor effect of CAR-T cells on gliomas. Front. Syst. Biol. 2, 923085 (2022).","journal-title":"Front. Syst. Biol."},{"key":"1809_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2023.1197310","volume":"3","author":"A Mazein","year":"2023","unstructured":"Mazein, A. et al. A guide for developing comprehensive systems biology maps of disease mechanisms: planning, construction and maintenance. Front. Bioinform. 3, 1197310 (2023).","journal-title":"Front. Bioinform."},{"key":"1809_CR58","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1080\/1547691X.2024.2345154","volume":"21","author":"A Mazein","year":"2024","unstructured":"Mazein, A. et al. Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways. J. Immunotoxicol. 21, S5\u2013S12 (2024).","journal-title":"J. Immunotoxicol."},{"key":"1809_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00610-z","volume":"5","author":"R Laubenbacher","year":"2022","unstructured":"Laubenbacher, R. et al. Building digital twins of the human immune system: toward a roadmap. npj Digit. Med. 5, 64 (2022).","journal-title":"npj Digit. Med."},{"key":"1809_CR60","unstructured":"Immune Digital Twins Working Group. Building an international and interdisciplinary community to develop immune digital twins for complex human pathologies. https:\/\/zenodo.org\/records\/10783684 (2024)."},{"key":"1809_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41746-025-01636-9","volume":"8","author":"M Ferle","year":"2025","unstructured":"Ferle, M. et al. Predicting progression events in multiple myeloma from routine blood work.npj Digit Med 8, 231 (2025).","journal-title":"npj Digit Med"},{"key":"1809_CR62","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura, F. et al. Genomic classification and individualized prognosis in multiple myeloma. J. Clin. Oncol. 42, 1229\u20131240 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1809_CR63","unstructured":"Oeser, A. et al. KAIT\u2014knowledge-driven and artificial intelligence-based platform for therapy decision support in hematology. White Paper. https:\/\/kait.health\/KAIT_White_Paper.pdf (2021)."},{"key":"1809_CR64","first-page":"9","volume":"42","author":"GA Halpern","year":"2025","unstructured":"Halpern, G. A., Nemet, M., Gowda, D. M., Kilickaya, O. & Lal, A. Advances and utility of digital twins in critical care and acute care medicine: a narrative review. J. Yeungnam Med. Sci. 42, 9 (2025).","journal-title":"J. Yeungnam Med. Sci."},{"key":"1809_CR65","doi-asserted-by":"publisher","DOI":"10.1177\/20552076241233998","volume":"10","author":"K Clo\u00df","year":"2024","unstructured":"Clo\u00df, K. et al. Application of wearables for remote monitoring of oncology patients: a scoping review. Digit. Health 10, 20552076241233998 (2024).","journal-title":"Digit. Health"},{"key":"1809_CR66","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2023-181936","volume":"142","author":"S Rajeeve","year":"2023","unstructured":"Rajeeve, S. et al. Early and consistent CRS detection using wearable device for remote patient monitoring following CAR-T therapy in relapsed\/refractory multiple myeloma (RRMM): early results of an investigator-initiated trial. Blood 142, 1007 (2023).","journal-title":"Blood"},{"key":"1809_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100705","volume":"38","author":"MG Hanna","year":"2025","unstructured":"Hanna, M. G. et al. Future of artificial intelligence-machine learning trends in pathology and medicine. Mod. Pathol. 38, 100705 (2025).","journal-title":"Mod. Pathol."},{"key":"1809_CR68","unstructured":"Center for Devices and Radiological Health. Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions. Guidance for Industry and Food and Drug Administration Staff. (FDA, 2023)."},{"key":"1809_CR69","doi-asserted-by":"publisher","first-page":"e1010541","DOI":"10.1371\/journal.pcbi.1010541","volume":"18","author":"S Galappaththige","year":"2022","unstructured":"Galappaththige, S., Gray, R. A., Costa, C. M., Niederer, S. & Pathmanathan, P. Credibility assessment of patient-specific computational modeling using patient-specific cardiac modeling as an exemplar. PLoS Comput. Biol. 18, e1010541 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"1809_CR70","doi-asserted-by":"publisher","unstructured":"Saldanha, O. L. et al. SwarmMAP: swarm learning for decentralized cell type annotation in single cell sequencing data. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.13.632775 (2025).","DOI":"10.1101\/2025.01.13.632775"},{"key":"1809_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03615-3","volume":"11","author":"CN Vorisek","year":"2024","unstructured":"Vorisek, C. N. et al. Towards an interoperability landscape for a national research data infrastructure for personal health data. Sci. Data 11, 772 (2024).","journal-title":"Sci. Data"},{"key":"1809_CR72","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202311799","volume":"19","author":"M Polychronidou","year":"2023","unstructured":"Polychronidou, M. et al. Single-cell biology: What does the future hold?. Mol. Syst. Biol. 19, e11799 (2023).","journal-title":"Mol. Syst. Biol."},{"key":"1809_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-1926-6","volume":"21","author":"D L\u00e4hnemann","year":"2020","unstructured":"L\u00e4hnemann, D. et al. Eleven grand challenges in single-cell data science. Genome Biol. 21, 31 (2020).","journal-title":"Genome Biol."},{"key":"1809_CR74","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41586-022-05046-9","volume":"608","author":"W Chen","year":"2022","unstructured":"Chen, W. et al. Live-seq enables temporal transcriptomic recording of single cells. Nature 608, 733\u2013740 (2022).","journal-title":"Nature"},{"key":"1809_CR75","doi-asserted-by":"publisher","first-page":"btae546","DOI":"10.1093\/bioinformatics\/btae546","volume":"40","author":"K Polanski","year":"2024","unstructured":"Polanski, K. et al. Bin2cell reconstructs cells from high resolution Visium HD data. Bioinformatics 40, btae546 (2024).","journal-title":"Bioinformatics"},{"key":"1809_CR76","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41592-023-01933-9","volume":"20","author":"IN Grabski","year":"2023","unstructured":"Grabski, I. N., Street, K. & Irizarry, R. A. Significance analysis for clustering with single-cell RNA-sequencing data. Nat. Methods 20, 1196\u20131202 (2023).","journal-title":"Nat. Methods"},{"key":"1809_CR77","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1093\/nar\/gkad1167","volume":"52","author":"PL Baldoni","year":"2024","unstructured":"Baldoni, P. L. et al. Dividing out quantification uncertainty allows efficient assessment of differential transcript expression with edgeR. Nucleic Acids Res. 52, e13 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1809_CR78","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/bioinformatics\/btab001","volume":"37","author":"S van Buren","year":"2021","unstructured":"van Buren, S. et al. Compression of quantification uncertainty for scRNA-seq counts. Bioinformatics 37, 1699\u20131707 (2021).","journal-title":"Bioinformatics"},{"key":"1809_CR79","doi-asserted-by":"publisher","unstructured":"Engelmann, J. et al. Uncertainty quantification for atlas-level cell type transfer. Preprint at arxiv https:\/\/doi.org\/10.48550\/arXiv.2211.03793 (2022).","DOI":"10.48550\/arXiv.2211.03793"},{"key":"1809_CR80","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41596-024-00972-6","volume":"19","author":"M Alieva","year":"2024","unstructured":"Alieva, M. et al. BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response. Nat. Protoc. 19, 2052\u20132084 (2024).","journal-title":"Nat. Protoc."},{"key":"1809_CR81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41590-023-01665-0","volume":"25","author":"P Hern\u00e1ndez-L\u00f3pez","year":"2024","unstructured":"Hern\u00e1ndez-L\u00f3pez, P. et al. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells. Nat. Immunol. 25, 88\u2013101 (2024).","journal-title":"Nat. Immunol."},{"key":"1809_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0158-1","volume":"2","author":"M Lehne","year":"2019","unstructured":"Lehne, M., Sass, J., Essenwanger, A., Schepers, J. & Thun, S. Why digital medicine depends on interoperability. npj Digit. Med. 2, 79 (2019).","journal-title":"npj Digit. Med."},{"key":"1809_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac212","volume":"23","author":"A Niarakis","year":"2022","unstructured":"Niarakis, A. et al. Addressing barriers in comprehensiveness, accessibility, reusability, interoperability and reproducibility of computational models in systems biology. Brief. Bioinform. 23, bbac212 (2022).","journal-title":"Brief. Bioinform."},{"key":"1809_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek, L., Jan\u017ei\u010d, L., Ihan, A. & Kopitar, A. N. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. Front. Immunol. 15, 1378944 (2024).","journal-title":"Front. Immunol."},{"key":"1809_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00553-6","volume":"8","author":"F Markowetz","year":"2024","unstructured":"Markowetz, F. All models are wrong and yours are useless: making clinical prediction models impactful for patients. npj Precis. Oncol. 8, 54 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1809_CR86","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer 2, 629\u2013642 (2021).","journal-title":"Nat. Cancer"},{"key":"1809_CR87","first-page":"96","volume":"29","author":"JH Moore","year":"2024","unstructured":"Moore, J. H. et al. SynTwin: a graph-based approach for predicting clinical outcomes using digital twins derived from synthetic patients. Pac. Symp. Biocomput. 29, 96\u2013107 (2024).","journal-title":"Pac. Symp. Biocomput."},{"key":"1809_CR88","doi-asserted-by":"publisher","unstructured":"Braun, T., Kuschel, F., Reiche, K., Merz, M. & Herling, M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia https:\/\/doi.org\/10.1038\/s41375-025-02574-x (2025).","DOI":"10.1038\/s41375-025-02574-x"},{"key":"1809_CR89","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","volume":"31","author":"T Braun","year":"2025","unstructured":"Braun, T. et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat. Med. 31, 1145\u20131153 (2025).","journal-title":"Nat. Med."},{"key":"1809_CR90","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"1809_CR91","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp7977","volume":"384","author":"EJ Topol","year":"2024","unstructured":"Topol, E. J. Medical forecasting. Science 384, eadp7977 (2024).","journal-title":"Science"},{"key":"1809_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-3449-3_4","volume":"2716","author":"S Ars\u00e8ne","year":"2024","unstructured":"Ars\u00e8ne, S. et al. In silico clinical trials: Is it possible?. Methods Mol. Biol. 2716, 51\u201399 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1809_CR93","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11095-022-03257-3","volume":"39","author":"JS Barrett","year":"2022","unstructured":"Barrett, J. S., Nicholas, T., Azer, K. & Corrigan, B. W. Role of disease progression models in drug development. Pharm. Res. 39, 1803\u20131815 (2022).","journal-title":"Pharm. Res."},{"key":"1809_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00517-w","volume":"8","author":"B Derraz","year":"2024","unstructured":"Derraz, B. et al. New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology. npj Precis. Oncol. 8, 23 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1809_CR95","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/cpt.3153","volume":"115","author":"N Terranova","year":"2024","unstructured":"Terranova, N. & Venkatakrishnan, K. Machine learning in modeling disease trajectory and treatment outcomes: an emerging enabler for model-informed precision medicine. Clin. Pharmacol. Ther. 115, 720\u2013726 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1809_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1688616","volume":"12","author":"AP Singh","year":"2020","unstructured":"Singh, A. P. et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. mAbs 12, 1688616 (2020).","journal-title":"mAbs"},{"key":"1809_CR97","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1109\/JBHI.2021.3090469","volume":"25","author":"M Viceconti","year":"2021","unstructured":"Viceconti, M. et al. Possible contexts of use for in silico trials methodologies: a consensus-based review. IEEE J. Biomed. Health Inform. 25, 3977\u20133982 (2021).","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"1809_CR98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1547691X.2024.2345158","volume":"21","author":"M Alb","year":"2024","unstructured":"Alb, M. et al. Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept. J. Immunotoxicol. 21, 13\u201328 (2024).","journal-title":"J. Immunotoxicol."},{"key":"1809_CR99","doi-asserted-by":"publisher","unstructured":"Mazein, A. et al. An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-5163108\/v1 (2024).","DOI":"10.21203\/rs.3.rs-5163108\/v1"},{"key":"1809_CR100","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17460441.2023.2273839","volume":"19","author":"M Bordukova","year":"2024","unstructured":"Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov. 19, 33\u201342 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"1809_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103605","volume":"28","author":"P Moingeon","year":"2023","unstructured":"Moingeon, P., Chenel, M., Rousseau, C., Voisin, E. & Guedj, M. Virtual patients, digital twins and causal disease models: paving the ground for in silico clinical trials. Drug Discov. Today 28, 103605 (2023).","journal-title":"Drug Discov. Today"},{"key":"1809_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1433372","volume":"11","author":"KI Aycock","year":"2024","unstructured":"Aycock, K. I. et al. Toward trustworthy medical device in silico clinical trials: a hierarchical framework for establishing credibility and strategies for overcoming key challenges. Front. Med. 11, 1433372 (2024).","journal-title":"Front. Med."},{"key":"1809_CR103","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"1809_CR104","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1809_CR105","doi-asserted-by":"publisher","first-page":"e002907","DOI":"10.1136\/rmdopen-2022-002907","volume":"9","author":"U Blache","year":"2023","unstructured":"Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D. & Fricke, S. CAR T cells for treating autoimmune diseases. RMD Open 9, e002907 (2023).","journal-title":"RMD Open"},{"key":"1809_CR106","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1809_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1289303","volume":"15","author":"E Morte-Romea","year":"2024","unstructured":"Morte-Romea, E. et al. CAR Immunotherapy for the treatment of infectious diseases: a systematic review. Front. Immunol. 15, 1289303 (2024).","journal-title":"Front. Immunol."},{"key":"1809_CR108","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/d41591-023-00042-6","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho, T. First two patients receive CAR T cell therapy for HIV. Nat. Med. 29, 1290\u20131291 (2023).","journal-title":"Nat. Med."},{"key":"1809_CR109","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1809_CR110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008566","volume":"12","author":"TB Shabaneh","year":"2024","unstructured":"Shabaneh, T. B. et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J. Immunother. Cancer 12, e008566 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1809_CR111","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","volume":"211","author":"M Bachmann","year":"2019","unstructured":"Bachmann, M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol. Lett. 211, 13\u201322 (2019).","journal-title":"Immunol. Lett."},{"key":"1809_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383894","volume":"15","author":"LS Schlegel","year":"2024","unstructured":"Schlegel, L. S., Werbrouck, C., Boettcher, M. & Schlegel, P. Universal CAR 2.0 to overcome current limitations in CAR therapy. Front. Immunol. 15, 1383894 (2024).","journal-title":"Front. Immunol."},{"key":"1809_CR113","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Investig. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Investig."},{"key":"1809_CR114","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","volume":"20","author":"S Mensurado","year":"2023","unstructured":"Mensurado, S., Blanco-Dom\u00ednguez, R. & Silva-Santos, B. The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178\u2013191 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1809_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/cancers8030036","volume":"8","author":"V Golubovskaya","year":"2016","unstructured":"Golubovskaya, V. & Wu, L. Different Subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers 8, 36 (2016).","journal-title":"Cancers"},{"key":"1809_CR116","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 10, 40 (2024).","DOI":"10.1038\/s41420-024-01815-9"},{"key":"1809_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","volume":"25","author":"SM Abdin","year":"2024","unstructured":"Abdin, S. M., Paasch, D. & Lachmann, N. CAR macrophages on a fast track to solid tumor therapy. Nat. Immunol. 25, 11\u201312 (2024).","journal-title":"Nat. Immunol."},{"key":"1809_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618427","volume":"11","author":"KJ Caldwell","year":"2020","unstructured":"Caldwell, K. J., Gottschalk, S. & Talleur, A. C. Allogeneic CAR cell therapy-more than a pipe dream. Front. Immunol. 11, 618427 (2020).","journal-title":"Front. Immunol."},{"key":"1809_CR119","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I. & Sadelain, M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 13, 829\u2013843 (2023).","journal-title":"Cancer Discov."},{"key":"1809_CR120","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1809_CR121","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"1809_CR122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-0716-2441-8_3","volume":"2521","author":"S Prommersberger","year":"2022","unstructured":"Prommersberger, S. et al. Generation of CAR-T cells with sleeping beauty transposon gene transfer. Methods Mol. Biol. 2521, 41\u201366 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1809_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat, Y. et al. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci. 348, 122683 (2024).","journal-title":"Life Sci."},{"key":"1809_CR124","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609, 369\u2013374 (2022).","journal-title":"Nature"},{"key":"1809_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45197-x","volume":"13","author":"Auw","year":"2023","unstructured":"Auw et al. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality. Sci. Rep. 13, 18160 (2023).","journal-title":"Sci. Rep."},{"key":"1809_CR126","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s42003-023-04978-w","volume":"6","author":"SP Fraessle","year":"2023","unstructured":"Fraessle, S. P. et al. Activation-inducible CAR expression enables precise control over engineered CAR T cell function. Commun. Biol. 6, 604 (2023).","journal-title":"Commun. Biol."},{"key":"1809_CR127","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","volume":"28","author":"S Prommersberger","year":"2021","unstructured":"Prommersberger, S. et al. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther. 28, 560\u2013571 (2021).","journal-title":"Gene Ther."},{"key":"1809_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020).","journal-title":"Nat. Commun."},{"key":"1809_CR129","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai, C. J. et al. In vivo CAR T-cell generation in non-human primates using lentiviral vectors displaying a multi-domain fusion ligand. Blood 144, 977\u2013987 (2024).","journal-title":"Blood"},{"key":"1809_CR130","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/jamia\/ocy032","volume":"25","author":"JM Reps","year":"2018","unstructured":"Reps, J. M., Schuemie, M. J., Suchard, M. A., Ryan, P. B. & Rijnbeek, P. R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J. Am. Med. Inform. Assoc. 25, 969\u2013975 (2018).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1809_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103239","volume":"96","author":"JL Warner","year":"2019","unstructured":"Warner, J. L. et al. HemOnc: a new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J. Biomed. Inform. 96, 103239 (2019).","journal-title":"J. Biomed. Inform."},{"key":"1809_CR132","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/CCI.20.00079","volume":"5","author":"R Belenkaya","year":"2021","unstructured":"Belenkaya, R. et al. Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin. Cancer Inform. 5, 12\u201320 (2021).","journal-title":"JCO Clin. Cancer Inform."},{"key":"1809_CR133","unstructured":"OHDSI. OMOP Common Data Model Oncology Extension. OMOP Common Data Model Oncology Extension. https:\/\/ohdsi.github.io\/CommonDataModel\/oncology.html (2024)."},{"key":"1809_CR134","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.2196\/13249","volume":"21","author":"SJ Shin","year":"2019","unstructured":"Shin, S. J. et al. Genomic common data model for seamless interoperation of biomedical data in clinical practice: retrospective study. J. Med. Internet Res. 21, e13249 (2019).","journal-title":"J. Med. Internet Res."},{"key":"1809_CR135","unstructured":"ISO\/TS 20428:2024. Genomics informatics\u2014data elements and their metadata for describing structured clinical genomic sequence information in electronic health records. International Organization for Standardization (2024)."},{"key":"1809_CR136","doi-asserted-by":"publisher","first-page":"e0285433","DOI":"10.1371\/journal.pone.0285433","volume":"18","author":"D Danis","year":"2023","unstructured":"Danis, D. et al. Phenopacket-tools: Building and validating GA4GH Phenopackets. PLoS ONE 18, e0285433 (2023).","journal-title":"PLoS ONE"},{"key":"1809_CR137","unstructured":"ISO 4454:2022. Genomics informatics\u2014phenopackets: a format for phenotypic data exchange. International Organization for Standardization (2022)."},{"key":"1809_CR138","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-024-02532-y","volume":"22","author":"K Hrovatin","year":"2025","unstructured":"Hrovatin, K. et al. Considerations for building and using integrated single-cell atlases. Nat. Methods 22, 41\u201357 (2025).","journal-title":"Nat. Methods"},{"key":"1809_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-020-0115-6","volume":"5","author":"G Alterovitz","year":"2020","unstructured":"Alterovitz, G. et al. FHIR Genomics: enabling standardization for precision medicine use cases. npj Genom. Med. 5, 13 (2020).","journal-title":"npj Genom. Med."},{"key":"1809_CR140","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41436-020-01056-y","volume":"23","author":"KS Lau-Min","year":"2021","unstructured":"Lau-Min, K. S. et al. Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genet. Med. 23, 603\u2013605 (2021).","journal-title":"Genet. Med."},{"key":"1809_CR141","doi-asserted-by":"publisher","first-page":"e42621","DOI":"10.2196\/42621","volume":"25","author":"J Matschinske","year":"2023","unstructured":"Matschinske, J. et al. The FeatureCloud platform for federated learning in biomedicine: unified approach. J. Med. Internet Res. 25, e42621 (2023).","journal-title":"J. Med. Internet Res."},{"key":"1809_CR142","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.drudis.2022.01.007","volume":"27","author":"CHS King","year":"2022","unstructured":"King, C. H. S. et al. Communicating regulatory high-throughput sequencing data using BioCompute Objects. Drug Discov. Today 27, 1108\u20131114 (2022).","journal-title":"Drug Discov. Today"},{"key":"1809_CR143","volume":"38","author":"S Banerjee","year":"2024","unstructured":"Banerjee, S., Jesubalan, N. G., Kulkarni, A., Agarwal, A. & Rathore, A. S. Developing cyber-physical system and digital twin for smart manufacturing: Methodology and case study of continuous clarification. J. Ind. Inf. Integr. 38, 100577 (2024).","journal-title":"J. Ind. Inf. Integr."},{"key":"1809_CR144","doi-asserted-by":"publisher","first-page":"16749","DOI":"10.1109\/JIOT.2021.3051158","volume":"8","author":"H Elayan","year":"2021","unstructured":"Elayan, H., Aloqaily, M. & Guizani, M. Digital twin for intelligent context-aware iot healthcare systems. IEEE Internet Things J. 8, 16749\u201316757 (2021).","journal-title":"IEEE Internet Things J."},{"key":"1809_CR145","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s10796-022-10252-x","volume":"26","author":"SJ Oks","year":"2024","unstructured":"Oks, S. J. et al. Cyber-physical systems in the context of Industry 4.0: a review, categorization and outlook. Inf. Syst. Front. 26, 1731\u20131772 (2024).","journal-title":"Inf. Syst. Front."},{"key":"1809_CR146","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2024-203013","volume":"144","author":"A Vanhellemont","year":"2024","unstructured":"Vanhellemont, A. et al. Remote patient monitoring for early detection of cytokine release syndrome in myeloma patients: a comparative study between standard care and remote monitoring. Blood 144, 3664 (2024).","journal-title":"Blood"},{"key":"1809_CR147","unstructured":"Article 29 Data Protection Working Party. Opinion 05\/2014 on Anonymisation Techniques. https:\/\/ec.europa.eu\/justice\/article-29\/documentation\/opinion-recommendation\/files\/2014\/wp216_en.pdf, 10 (2014)."},{"key":"1809_CR148","first-page":"124","volume":"8","author":"A Gobert","year":"2024","unstructured":"Gobert, A., Knockaert, M., Martin, R. & Van Gyseghem, J.-M. La donn\u00e9e \u00e0 caract\u00e8re personnel et sa r\u00e9utilisation.J. Trib 8, 124\u2013127 (2024).","journal-title":"J. Trib"},{"key":"1809_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2022.104096","volume":"131","author":"S Zenker","year":"2022","unstructured":"Zenker, S. et al. Data protection-compliant broad consent for secondary use of health care data and human biosamples for (bio)medical research: Towards a new German national standard. J. Biomed. Inform. 131, 104096 (2022).","journal-title":"J. Biomed. Inform."},{"key":"1809_CR150","unstructured":"ISO\/TS 9491-1:2023. Biotechnology\u2014predictive computational models in personalized medicine research. International Organization for Standardization (2023)."},{"key":"1809_CR151","unstructured":"FDA. Artificial intelligence and machine learning in software as a medical device. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-and-machine-learning-software-medical-device#regulation (2024)."},{"key":"1809_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01213-6","volume":"7","author":"F Busch","year":"2024","unstructured":"Busch, F. et al. Navigating the European Union artificial intelligence act for healthcare. npj Digit. Med. 7, 210 (2024).","journal-title":"npj Digit. Med."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01809-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:54:47Z","timestamp":1757336087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01809-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":152,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1809"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01809-6","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.A. received speaker honoraria from Janssen Pharmaceutica NV. H.F. received funding from UCB Pharma and AbbVie for research purposes. S.Fri. received speaker's fees from Novartis Pharma GmbH, Janssen-Cilag GmbH, Vertex Pharmaceuticals (Germany) GmbH, Kite\/Gilead Sciences GmbH, MSGO GmbH, Bristol-Myers Squibb GmbH & Co. KGaA and art tempi Communications. L.G.: Janssen, BMS, Sanofi, Pfizer. M.H. is an inventor on patent applications and has been granted patents related to CAR technology, licensed in part to industry. M.H. is a cofounder and equity owner of T-CURX GmbH, W\u00fcrzburg. M.H. receives speaker honoraria from BMS, Janssen, Kite\/Gilead, and Novartis and research support from BMS. J.R.H receives research funding from Adaptive Biotechnologies, BioLinRx, Sanofi, GlaxoSmithKline, Regeneron, Pfizer, Johnson and Johnson Innovative Medicine, and Takeda Oncology. U.K. has received consultant and\/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, CGT manufacturing: Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. J.K. is shareholder on follow up companies of Gadeta, inventor on multiple patents dealing with genetic engineering of immune cells, received research support from Novartis, Miltenyi Biotech, and Gadeta. Maximilian Merz: Advisory Boards\/Honoraria\/Research support: Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks, Takeda, and Roche\/Genentech. A.N. collaborates with SANOFI-AVENTIS R&D via a public\u2013private partnership grant CIFRE contract, n\u00b0 2020\/0766. O.P. has received grants and personal fees from Incyte, Neovii, Gilead, Merck Sharpe and Dohme, Omeros, Sobi, Takeda, and Jazz Pharmaceuticals. U.O. has received honoraria and research support from BMS, Johnson-Johnson, Gilead. A.S. is a shareholder and managing director of Springboard Health Angels, Schmidt Deng Ventures and their respective venture funds and portfolio companies. D.S. is shareholder at Masaryk University spinoff: Institute of Biostatistics and Analyses. Z.S. is inventor on multiple patents dealing with genetic engineering of immune cells. K.R. received honoraria from Novartis Pharma GmbH. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}